Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth ...

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 10 Stocks Delivering Eye-Popping Gains. Hims & Hers rebounded by 11.76 ...

Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy used for weight loss since late April in order to ...